CANNABIDIOL

Brand name:

• Epidyolex®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

Chiesi Australia Pty Ltd

Condition/indication:
(therapeutic use)

• Lennox-Gastaut syndrome

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

Change to listing (–)

Comment:

--

Other PBAC consideration:

• CANNABIDIOL

Submission received for:

September 2022 PBAC meeting

Opportunity for consumer comment:

Open 30/03/2022 and close 25/05/2022 (see PBS Website)

PBAC meeting:

Held on 02/09/2022

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

24/11/2022

Lodgement of required documentation:

30/11/2022

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 24/02/2023

Status:

Finalised

Government processes:

Commenced on 17/03/2023

Medicine listed on the PBS:

01/06/2023 (see PBS schedule)